At a global level, Teva has one of the broadest medicines pipelines in the industry, and in the UK Teva is one of the largest suppliers of medicines to the NHS.
That means we can be in a strong position to bring generic versions of branded medicines to market on the first day of patent protection ending. Generic medicines are typically sold at a substantially lower price to their branded medicine counterparts, as the development process is generally less costly.
Generic medicines bring significant savings to the NHS medicines bill – estimates are that generic medicines save the NHS over £13 billion every year,1 compared to the cost if their branded equivalents had been dispensed. This frees up valuable NHS budgets.
 https://www.thetimes.co.uk/article/nhs-costs-to-soar-as-drugs-become-more-complex-z2688zz3w8t [Last accessed 10.04.2018]